trending Market Intelligence /marketintelligence/en/news-insights/trending/fZlMLnpdwx3T6SyBC8fQ1A2 content esgSubNav
In This List

NICE approves use of Merck's Keytruda under cancer fund

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


NICE approves use of Merck's Keytruda under cancer fund

The U.K.'s National Institute for Health and Care Excellence cleared the use of Merck & Co. Inc.'s cancer drug Keytruda in previously untreated lung cancer patients under funding arrangements within the Cancer Drugs Fund, Reuters reported.

The agency did not recommend the routine use of the drug for newly diagnosed patients due to its high cost and uncertainties about overall survival benefits.